The HRD Decision-Which PARP Inhibitor to Use for Whom and When.

Abstract

Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. Clin Cancer Res; 23(23); 7155-7. ©2017 AACRSee related article… (More)
DOI: 10.1158/1078-0432.CCR-17-2186

Topics

  • Presentations referencing similar topics